UC San Diego Maps Genetic Drivers of Rare CMS Disorders

Researchers at UC San Diego have mapped the structural mechanisms behind congenital myasthenic syndromes (CMS), a rare group of inherited neuromuscular disorders, and identified an existing antidepressant as a candidate for repurposing. Published in Nature on 1 July 2026, the study provides a framework for precision medicine approaches to CMS by resolving 12 high-resolution structures of disease-causing acetylcholine receptor variants using cryo-electron microscopy.

CMS affects children from birth or early childhood, causing muscle weakness, difficulty walking, impaired breathing and in severe cases paralysis or death. The team, led by Ryan Hibbs at UC San Diego, used cryo-EM combined with electrophysiology and chemical biology to visualize the human acetylcholine receptor at near-atomic resolution. Two major forms of CMS arise through fundamentally different mechanisms. In “fast-channel” CMS, mutations prevent efficient receptor opening; the team discovered a previously unknown drug-binding pocket that responds to positive allosteric modulators, with different modulators working better for different patient mutations, an inherently precision medicine outcome.

In “slow-channel” CMS, receptors remain open too long, damaging the neuromuscular junction over time. The study explains how existing treatments quinidine and fluoxetine block the defective receptors, and identifies reboxetine, an antidepressant already approved in several countries, as a promising candidate for repurposing. Reboxetine selectively suppresses the abnormal receptor activity responsible for slow-channel disease, and because it has already undergone extensive safety testing, it could offer an accelerated regulatory path. Collaborators included Mayo Clinic and UC San Francisco, with funding from the NIH, Myasthenia Gravis Foundation of America and American Heart Association.

The commercial signal is around drug repurposing and precision medicine in rare disease. Reboxetine’s existing safety profile could compress the clinical development pathway significantly for slow-channel CMS, while the fast-channel finding creates a clear structural template for new small-molecule drug discovery. Both turn a poorly understood rare disease into a legitimately investable precision medicine opportunity for both large pharma and specialist rare disease biotechs.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!